

The PCORnet Antibiotics and Childhood Growth Study: Toward PCORnet Research Readiness

Christopher Forrest, MD, PhD

Jason Block, MD, MPH

L. Charles Bailey, MD, PhD

NIH Health Care Systems Research Collaboratory Grand Rounds

May 18, 2018



pcornetSM

**The National Patient-Centered
Clinical Research Network**

Talk Overview

- 🌐 Taking PCORnet for a Test Drive
- 🌐 Challenges of Working in a New Network
- 🌐 Results of the PCORnet Antibiotics and Childhood Growth Study
- 🌐 PCORnet Future Directions

PCORnet® Common Data Model domains

- Based on FDA Sentinel Common Data Model
- Licensed under Creative Commons (open-access, use, and share)
- Designed to promote multi-site, patient-centered research
- Allows for interoperability

PCORnet Common Data Model Domains, v3.0 and v3.1

DEMOGRAPHIC v1.0

Demographics record the direct attributes of individual patients.

ENROLLMENT v1.0

Enrollment is a concept that defines a period of time during which a person is expected to have complete data capture. This concept is often insurance-based, but other methods of defining enrollment are possible.

ENCOUNTER v1.0

Encounters are interactions between patients and providers within the context of healthcare delivery.

DIAGNOSIS v1.0

Diagnosis codes indicate the results of diagnostic processes and medical coding within healthcare delivery. Data in this table are expected to be from healthcare-mediated processes and reimbursement drivers.

PROCEDURES v1.0

Procedure codes indicate the discreet medical interventions and diagnostic testing, such as surgical procedures and lab orders, delivered within a healthcare context.

VITAL v1.0

Vital signs (such as height, weight, and blood pressure) directly measure an individual's current state of attributes.

LAB_RESULT_CM v2.0

Laboratory result Common Measures (CM) use specific types of quantitative and qualitative measurements from blood and other body specimens. The common measures are defined in the same way across all PCORnet networks, but this table can also include other types of lab results.

CONDITION v2.0

A condition represents a patient's diagnosed and self-reported health conditions and diseases. The patient's medical history and current state may both be represented.

PRO_CM v2.0

Patient-Reported Outcome (PRO) Common Measures (CM) are standardized measures that are defined in the same way across all PCORnet networks. Each measure is recorded at the individual item level: an individual question/statement, paired with its standardized response options.

DISPENSING v2.0

Outpatient pharmacy dispensing, such as prescriptions filled through a neighborhood pharmacy with a claim paid by an insurer. Outpatient dispensing may not be directly captured within healthcare systems.

PRESCRIBING v3.0

Provider orders for medication dispensing and/or administration. These orders may take place in any setting, including the inpatient or outpatient basis.

PCORNET_TRIAL v3.0

Patients who are enrolled in PCORnet clinical trials.

DEATH v3.0

Reported mortality information for patients.

DEATH_CAUSE v3.0

The individual causes associated with a reported death.

HARVEST v3.0

Attributes associated with the specific PCORnet datamart implementation, including data refreshes.

Antibiotics and Weight in Childhood

- 🌐 Biological premise related to alterations in microbiome affecting metabolism and direct growth promoting effects of antibiotics
- 🌐 Prior studies done in varied environments have been mixed
- 🌐 Meta-analysis of 15 studies
 - Mean BMI z-score: 0.07 (0.05, 0.09) higher with antibiotic exposure; significant higher association in 5 of 8 studies
 - Overweight/obesity: RR of 1.23 (1.13, 1.35); significantly higher RR in 6 of 9 studies


PCORnet Antibiotics Study

- 🌐 Aims: to assess the association between antibiotic use before age 2 and childhood weight outcomes:
 - Antibiotics use & weight outcomes at age 5 and 10
 - Antibiotics use & childhood weight trajectories
 - Incorporation of maternal variables in 7 DataMarts
- 🌐 Qualitative Aim:
 - Parent focus groups and provider interviews focusing on association between antibiotics and childhood obesity
- 🌐 Study setting and team
 - 36 healthcare institutions participating, 10 CDRNs

Site Selection Process

- 🌐 Data characterization to assess data quality and availability of vitals and prescribing data; counts of frequencies of outcomes and covariates
- 🌐 7 sites removed at this stage
 - 5 – data quality issues
 - 2 – unwilling to share individual-level data
- 🌐 Sites with any available data included
 - N range – 34 to 187,226
 - 14/36 institutions contributed 83% of data

Cohort Inclusion Flow Diagram



Key Challenges



pcornetSM

The National Patient-Centered
Clinical Research Network

It's Hard to Do Research on a Network While Building

- PCORnet provided extensive guidance to networks, but it takes some time (and frequent assessments) for all to implement
- Many source medication codes mapped to RxNorm codes, but use of codes varied, esp. specificity of codes
- Cannot always get details on medications, such as days supply
- Varied models of PCORnet Network Partners create different levels of transparency

Tracking Issues Encountered and Addressed

- 28 NPs of an initial 33 planned had some issues; 5 had to be removed
- 29 separate issues identified with prescribing tables – most resolved
- 6 issues with vitals tables, specifically height and weight – again, most resolved

Aim 1 Analysis: Antibiotics Use <24 Months & Weight Outcomes at Age 4 to <6



pcornetSM

The National Patient-Centered
Clinical Research Network

Primary Outcome/Aim Analysis

- 🌐 Outcome – Chose height/weight value closest to 60 months of age and calculated BMI z-score and weight status
- 🌐 Exposure – Antibiotics ≤ 24 months of age, yes v. no
- 🌐 Covariates
 - Demographics: gender, race, Hispanic
 - Clinical: # of visits, asthma diagnosis, prematurity diagnosis, corticosteroid use, # of infections (mediator)

Secondary and Sensitivity Analyses

Secondary analyses

- Narrow (amoxicillin, penicillin) and broad
- Age-specific exposure (0-<6 mos, 6-<12 mos, 12-<24 mos)
- Dose response from 0 to 4+


Sensitivity analyses

- Prescriptions only for less severe infections
- Children with at least one well-child visit documented
- Data Partners with over 40% antibiotics prescribing

Results: Table 1

Gender	Male	52%
	Female	48%
Race	White	53%
	Black, African American	27%
	Refuse/Unknown/No info	8%
	Other/Multiple Race	8%
	Asian	4%
Hispanic	No/Unknown	82%
	Yes	18%
Diagnoses	Complex Chronic Condition	14%
	Asthma	13%
	Prematurity	7%

Antibiotic Prescribing Rate Differed by Network Partner




Results: Multivariable Regression, Any Antibiotics <24 months and BMI z-score Parameter Estimates

Type of Antibiotic	No Complex Condition	Complex Condition
All	0.05 (0.04, 0.06)	0.07 (0.05, 0.10)
Broad	0.05 (0.04, 0.06)	0.08 (0.06, 0.10)
Narrow	0.03 (0.02, 0.04)	0.04 (0.00, 0.07)

*Adjusted for sex, race, ethnicity, # clinical encounters, steroid use, asthma, prematurity

Results: Multivariable Regression, Dose Response



Conclusions

- ❁ Limited association between antibiotics in early life and weight outcomes at age 4 to <6 years
- ❁ Clinical implication of this likely negligible; population effect uncertain

Workflow in Aim 1 Aggregate Analysis

Patient-level analytic dataset stored locally at each data mart

Main analysis

DataMarts return patient-level analytic dataset above to study team

Study team pools all the patient-level analytic datasets

Study team executes a program against the pooled patient-level dataset to generate effect estimates and 95% CIs

Aggregate Analysis

DataMarts execute a distributed program locally against its analytic data set above

DataMarts return requested aggregate output to the study team

Study team executes a program centrally against the returned aggregate output to generate effect estimates and 95% CIs

Results: Main Analysis vs. Aggregate Analysis – Model 1*

* No complex chronic conditions, binary exposure (any antibiotics <24 months vs. none)

Select variables	Parameter estimate		Standard error		t-value	
	Main		Main		Main	
Variable 1	0.17399		0.04962		3.51	
Variable 2	0.04280		0.00496		8.62	
Variable 3	0.02114		0.00435		4.86	
Variable 4	-0.22029		0.00940		-23.45	

Results: Main Analysis vs. Aggregate Analysis – Model 1*

* No complex chronic conditions, binary exposure (any antibiotics <24 months vs. none)

Select variables	Parameter estimate		Standard error		t-value	
	Main	Aggregate	Main	Aggregate	Main	Aggregate
Variable 1	0.17399	0.17399	0.04962	0.04962	3.51	3.51
Variable 2	0.04280	0.04280	0.00496	0.00496	8.62	8.62
Variable 3	0.02114	0.02114	0.00435	0.00435	4.86	4.86
Variable 4	-0.22029	-0.22029	0.00940	0.00940	-23.45	-23.45

Results: Main Analysis vs. Aggregate Analysis – Model 1*

* No complex chronic conditions, binary exposure (any antibiotics <24 months vs. none)

Select variables	Parameter estimate		Standard error		t-value	
	Main	Aggregate	Main	Aggregate	Main	Aggregate
Variable 1	0.17399	0.17399	0.04962	0.04962	3.51	3.51
Variable 2	0.04280	0.04280	0.00496	0.00496	8.62	8.62
Variable 3	0.02114	0.02114	0.00435	0.00435	4.86	4.86
Variable 4	-0.22029	-0.22029	0.00940	0.00940	-23.45	-23.45

Maximum difference in all 39 variables in the model: 3.8906E-10

Summary of Findings from the Other 11 Models

- Results are highly comparable
- Estimates from aggregate analysis differed from estimates in the main analysis at the 10th decimal place or further

Aim 2 Analysis: Antibiotics Use & childhood weight trajectories



pcornetSM

**The National Patient-Centered
Clinical Research Network**


Trajectory Analysis Objectives

- Assess age-sex-height standardized weight trajectory over several years following antibiotic exposure ≤ 2 years
- Examine age-sex-height standardized weight trajectory immediately following antibiotic administration

Ht/Wt Data Quality Assessment


- 🌐 CDC thresholds for Biologically Implausible Values (identical to Aim 1)
 - Retained 96% (ht) / 99% (wt) as plausible measurements
- 🌐 Longitudinal (within-person) errors – Daymont *et al.* 2017
 - Probable unit conversion errors
 - Probable reuse of existing values
 - Outliers within an individual's trajectory
 - Inconsistency between height and weight

Error Correlation by Data Source




NHANES 2009-14 Comparison

Height




Weight




Drug Exposure DQA

- 🌐 Average abx rate for population (51%) has face validity
 - Small variations likely represent practice patterns
 - Large variations more likely to represent data collection problem or non-representative population
- 🌐 Measure data quality as distance from the mean

Drug Exposure DQA



Drug Exposure DQA




Aim 2 Cohort Selection

	n	Loss	Retained %
# of unique patients in PCORnet dataset	683,485	—	—
2 + plausible height and weight > 24 mos with Height/ Weight <30 days apart	682,162	1,323	99.1
>=2 Height/ Weight >=6 mos apart in outcome window	497,324	186,161	72.76
Longitudinal Data Cleaning	489,792	193,693	71.66
Data Quality Assessment	445,700	237,785	65.21

Approach

- Longitudinal Rate Regression (LRR)
 - Non-linear model
 - General function for longitudinal trajectories e.g. regression splines
 - Proportional Rate Assumption
 - Characterizes differences in rates of change as a percentage relative to a reference group
 - Account for confounders
 - Mean Level
 - Rate Level

Proportional Rate Assumption




Fully adjusted models controlled for:

- Sex
- Height
- Race/Ethnicity
- Asthma
- Oral Steroids (0,1,2,3,4+)
- Anti-Reflux Medications (0,1,2,3,4+)
- Infectious Visits (0,1,2,3,4+)
- Chronic Condition
- Preterm

Rate Δ – Count of Antibiotic Episodes

Fully Adjusted Model Results



Data Marts

Conclusions

- ⊕ Significant variability across network partners in data quality
- ⊕ Impact of any antibiotic exposure small, though detectable
- ⊕ Adjustment for clinical covariates centers variation, but does not change range
- ⊕ Analysis incorporating degree of exposure ongoing
- ⊕ Follow-on analyses for short-term effects

Aim 3: Maternal-Child Linkage Analysis

Led by Bill Heerman (Vanderbilt), Jason Block (HPHC), Matt Daley (PORTAL), Janne Boone-Heinonen (ADVANCE)



pcornetSM

**The National Patient-Centered
Clinical Research Network**


Maternal-Child Linkage Aim

- 🌐 Examine association of maternal antibiotics during pregnancy and child weight outcomes at age 4 to <6 yrs
- 🌐 Re-examine child antibiotics and weight association, incorporating specified maternal covariates
 - Pre-pregnancy BMI and gestational weight gain
 - Diabetes and gestational diabetes
 - Maternal smoking status
- 🌐 7 sites participating


Ancillary Table Elements Captured During Linkage

All Sites	Most but Not All Sites
Pre-pregnancy BMI	Type of delivery
Gestational weight gain	Smoking during pregnancy
Gestational diabetes	Infant birth weight*
Antibiotics during pregnancy	Gestational age at birth*

Percentage of Linked Mother-Child Pairs



Maternal Antibiotics During Pregnancy



Results: Abx During Pregnancy on Child BMI z-score at 4 to <6 years

	Parameter Est.	95% CI
Any Antibiotics	0.00	-0.03, 0.03
1 course	0.00	-0.03, 0.04
2 courses	-0.02	-0.08, 0.03
3 courses	-0.06	-0.14, 0.03
4+ courses	0.03	-0.09, 0.14
Any Broad	0.00	-0.03, 0.03
Any Narrow	-0.01	-0.07, 0.05

Qualitative Aim: Parent and Provider Assessments of Antibiotics and Obesity Risk

Research and analysis completed by: Ellen A. Lipstein, MD MPH; Bill Heerman, MD, MPH; Cassandra Dodds; J. Kiely Law; Douglas Lunsford; Paula Winkler; Jonathan A. Finkelstein, MD, MPH



pcornetSM

**The National Patient-Centered
Clinical Research Network**

Study Purpose

- 🌐 Understand parents' and providers' beliefs about risks and benefits of antibiotic use
- 🌐 Explore how a potential risk of future obesity would be perceived and integrated into parents' and providers' decision making

Summary of Qualitative Findings

- ❁ In setting of acute illness for their children, the long-term impact of obesity is not a major factor in parent or physician decision making.
- ❁ Parents/providers are pretty skeptical about an abx-weight association; would need to see huge effects to consider it.
- ❁ Differences in assessments of risk and benefit are wide – maybe hard to overcome for any small risk factor.

PCORnet Opportunities

- 🌐 Data quality improved in short time – still relatively early days but felt confident in final data (as did bariatric team)
- 🌐 Need to assess data on a study-by-study basis, perhaps before grants go in, to decide which sites to include
- 🌐 Opportunities for important studies moving forward - Patient-Centered Research Foundation will drive research focus and sustainability
- 🌐 Academic model creates complexity – how to pay on soft money model and give academic recognition for multi-institutional research

Thanks to the 28 Participating Network Partners, 36 Healthcare Institutions

Boston Medical (ARCH)

Wake Forest (ARCH)

ADVANCE

OneFlorida

Greenway (Mid-South)

UNC (Mid-South)

Vanderbilt (Mid-South)

Baylor Univ (REACHnet)

Ochsner Clinic (REACHnet)

Tulane (REACHnet)

PEDSnet (PEDSnet)

Cincinnati Childrens (PEDSnet)

Denver Health (PORTAL)

KP Washington (PORTAL)

Health Partners (PORTAL)

KP Colorado (PORTAL)

KP Mid-Atlantic (PORTAL)

KP Northwest (PORTAL)

NYC-CDRN

Marshfield Clinic (GPC)

Medical College of WI (GPC)

Univ of Iowa (GPC)

UT San Antonio (GPC)

Loyola Medicine (CAPriCORN)

Lurie Childrens (CAPriCORN)

North Shore (CAPriCORN)

Rush Univ (CAPriCORN)

Univ of Chicago (CAPriCORN)

Thank You!

Jason Block – jblock1@partners.org

Charles Bailey – baileyc@email.chop.edu

Chris Forrest – forrestc@email.chop.edu



pcornetSM

**The National Patient-Centered
Clinical Research Network**